Study: Ocriplasmin achieves better VMT release rates than in MIVI-TRUST, but concerns remain

SAN FRANCISCO — Greater rates of vitreomacular traction release were achieved with ocriplasmin compared with rates reported in the MIVI-TRUST studies, according to a study presented here, yet concerns remain regarding treatment-related adverse events, particularly loss of visual acuity.“Ocriplasmin for VMT release was effective in 45% of eyes, higher than what was seen in the MIVI-TRUST studies and also higher than what is seen in natural history,” Jennifer I. Lim, MD, said at the American Society of Retina Specialists annual meeting, where she reported results of a Macula Society retrospective collaborative review. “However, of concern is that we did see that complications were not uncommon.”